SG10201804326SA - Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor - Google Patents

Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Info

Publication number: SG10201804326SA
Authority: SG; Singapore
Prior art keywords: mediated rejection; methods; organ transplant; transplant patients; esterase inhibitor
Prior art date: 2013-11-22

Application number

SG10201804326SA

Other languages

English (en)

Inventor

Colin Broom

Marc Uknis

Original Assignee

Shire Viropharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-11-22

Filing date

2014-11-21

Publication date

2018-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52016153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201804326S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-11-21 Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc

2018-06-28 Publication of SG10201804326SA publication Critical patent/SG10201804326SA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Developmental Biology & Embryology (AREA)
Virology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Microbiology (AREA)
Mycology (AREA)
Transplantation (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SG10201804326SA 2013-11-22 2014-11-21 Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor SG10201804326SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361907550P	2013-11-22	2013-11-22
US201462029086P	2014-07-25	2014-07-25

Publications (1)

Publication Number	Publication Date
SG10201804326SA true SG10201804326SA (en)	2018-06-28

Family

ID=52016153

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG10201804326SA SG10201804326SA (en)	2013-11-22	2014-11-21	Methods of treating antibody-mediated rejection in organ transplant patients with c1-esterase inhibitor

Country Status (24)

Country	Link
US (3)	US9895428B2 (de)
EP (3)	EP3494988B1 (de)
JP (5)	JP6431912B2 (de)
KR (2)	KR102312817B1 (de)
CN (2)	CN111388655A (de)
AU (2)	AU2014352846B2 (de)
BR (1)	BR112016011499A2 (de)
CA (1)	CA2930964A1 (de)
CY (1)	CY1121298T1 (de)
DK (1)	DK3071219T3 (de)
ES (1)	ES2708655T3 (de)
HR (1)	HRP20190184T1 (de)
HU (1)	HUE041809T2 (de)
LT (1)	LT3071219T (de)
ME (1)	ME03318B (de)
MX (2)	MX378834B (de)
NZ (2)	NZ759187A (de)
PL (1)	PL3071219T3 (de)
PT (1)	PT3071219T (de)
RS (1)	RS58343B1 (de)
SG (1)	SG10201804326SA (de)
SI (1)	SI3071219T1 (de)
SM (1)	SMT201900042T1 (de)
WO (1)	WO2015077543A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ME03318B (de) *	2013-11-22	2019-10-20	Shire Viropharma Inc	Verfahren zur behandlung von antikörper-vermittelter abstossung bei organtransplantatpatienten mit c1-esterase-inhibitor
CA3075686A1 (en)	2017-09-15	2019-03-21	Cedars-Sinai Medical Center	Methods for improving organ function in organ transplant patients
WO2019166572A1 (en) *	2018-02-28	2019-09-06	Pharming Intellectual Property B.V.	Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
KR20210106521A (ko) *	2018-12-20	2021-08-30	세다르스-신나이 메디칼 센터	기관 이식체의 만성 항체 매개된 거부의 치료에서 클라자키주맙
CA3148600A1 (en) *	2019-08-08	2021-02-11	Cedars-Sinai Medical Center	Methods of improving organ function
EP3895726A1 (de)	2020-04-17	2021-10-20	Pharming Intellectual Property BV	Verwendung von c1-esterase-inhibitoren zur behandlung von akuter atemnot im zusammenhang mit virusinfektionen
CN116568327A (zh) *	2020-11-20	2023-08-08	德国杰特贝林生物制品有限公司	治疗抗体介导的排斥反应的方法
CN113035369B (zh) *	2021-03-10	2021-12-03	浙江大学	一种肾移植抗感染药物剂量预测模型的构建方法
JP2024525084A (ja)	2021-07-09	2024-07-09	ファーミング・インテレクチュアル・プロパティー・ビー．ブイ．	Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療
WO2024152030A1 (en) *	2023-01-13	2024-07-18	The Uab Research Foundation	Crossmatching for porcine xenotransplantation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4212278B2 (ja) *	2001-03-01	2009-01-21	日本たばこ産業株式会社	移植片拒絶反応抑制剤
DE10112617A1 (de) *	2001-03-14	2002-10-02	Aventis Behring Gmbh	Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
CA2654446C (en)	2005-06-07	2014-02-25	The Regents Of The University Of Colorado	Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
BRPI0708424A2 (pt) *	2006-03-02	2011-05-31	Alexion Pharma Inc	prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
DK2758076T3 (en) *	2011-09-24	2019-04-01	Csl Behring Gmbh	COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
WO2014135694A1 (en) *	2013-03-08	2014-09-12	Csl Behring Ag	Treatment and prevention of remote ischemia-reperfusion injury
ME02865B (de) *	2013-03-15	2018-04-20	Shire Viropharma Inc	C1-inh-zusammensetzungen zur vorbeugung und behandlung von herditärem angioödem
ME03318B (de)	2013-11-22	2019-10-20	Shire Viropharma Inc	Verfahren zur behandlung von antikörper-vermittelter abstossung bei organtransplantatpatienten mit c1-esterase-inhibitor

2014
- 2014-11-21 ME MEP-2019-31A patent/ME03318B/de unknown
- 2014-11-21 ES ES14809567T patent/ES2708655T3/es active Active
- 2014-11-21 NZ NZ759187A patent/NZ759187A/en unknown
- 2014-11-21 LT LTEP14809567.2T patent/LT3071219T/lt unknown
- 2014-11-21 MX MX2016006656A patent/MX378834B/es unknown
- 2014-11-21 KR KR1020167013463A patent/KR102312817B1/ko active Active
- 2014-11-21 CA CA2930964A patent/CA2930964A1/en not_active Abandoned
- 2014-11-21 PT PT14809567T patent/PT3071219T/pt unknown
- 2014-11-21 US US14/550,075 patent/US9895428B2/en active Active
- 2014-11-21 EP EP18205998.0A patent/EP3494988B1/de active Active
- 2014-11-21 HU HUE14809567A patent/HUE041809T2/hu unknown
- 2014-11-21 WO PCT/US2014/066784 patent/WO2015077543A1/en not_active Ceased
- 2014-11-21 BR BR112016011499-0A patent/BR112016011499A2/pt not_active Application Discontinuation
- 2014-11-21 KR KR1020217032180A patent/KR102384814B1/ko active Active
- 2014-11-21 NZ NZ719724A patent/NZ719724A/en unknown
- 2014-11-21 EP EP22188379.6A patent/EP4162947A1/de not_active Withdrawn
- 2014-11-21 PL PL14809567T patent/PL3071219T3/pl unknown
- 2014-11-21 CN CN202010018792.0A patent/CN111388655A/zh active Pending
- 2014-11-21 DK DK14809567.2T patent/DK3071219T3/en active
- 2014-11-21 CN CN201480063697.5A patent/CN105744949A/zh active Pending
- 2014-11-21 RS RS20190148A patent/RS58343B1/sr unknown
- 2014-11-21 EP EP14809567.2A patent/EP3071219B1/de not_active Revoked
- 2014-11-21 AU AU2014352846A patent/AU2014352846B2/en active Active
- 2014-11-21 SG SG10201804326SA patent/SG10201804326SA/en unknown
- 2014-11-21 SM SM20190042T patent/SMT201900042T1/it unknown
- 2014-11-21 SI SI201431066T patent/SI3071219T1/sl unknown
- 2014-11-21 JP JP2016532586A patent/JP6431912B2/ja active Active
- 2014-11-21 HR HRP20190184TT patent/HRP20190184T1/hr unknown
2016
- 2016-05-20 MX MX2021000332A patent/MX2021000332A/es unknown
2017
- 2017-12-18 US US15/844,850 patent/US20180104319A1/en not_active Abandoned
2018
- 2018-10-15 JP JP2018194167A patent/JP6620206B2/ja active Active
- 2018-11-15 JP JP2018214342A patent/JP2019023233A/ja not_active Withdrawn
2019
- 2019-01-29 CY CY20191100119T patent/CY1121298T1/el unknown
2020
- 2020-01-02 AU AU2020200015A patent/AU2020200015B2/en active Active
- 2020-08-03 US US16/983,998 patent/US20200360495A1/en not_active Abandoned
2021
- 2021-01-29 JP JP2021012833A patent/JP2021063141A/ja not_active Withdrawn
2022
- 2022-10-11 JP JP2022163044A patent/JP2022179637A/ja active Pending

Also Published As

Publication number	Publication date
HRP20190184T1 (hr)	2019-03-22
AU2014352846A1 (en)	2016-06-02
HUE041809T2 (hu)	2019-05-28
KR20210125118A (ko)	2021-10-15
DK3071219T3 (en)	2019-02-25
KR102312817B1 (ko)	2021-10-13
EP3071219B1 (de)	2018-11-14
SI3071219T1 (sl)	2019-03-29
JP2016537380A (ja)	2016-12-01
EP3494988B1 (de)	2022-08-03
EP4162947A1 (de)	2023-04-12
JP2019001831A (ja)	2019-01-10
NZ719724A (en)	2022-08-26
WO2015077543A1 (en)	2015-05-28
JP6620206B2 (ja)	2019-12-11
EP3494988A1 (de)	2019-06-12
JP6431912B2 (ja)	2018-11-28
AU2020200015A1 (en)	2020-01-30
ME03318B (de)	2019-10-20
AU2014352846B2 (en)	2019-10-03
AU2020200015B2 (en)	2022-03-10
MX378834B (es)	2025-03-11
MX2021000332A (es)	2021-04-13
MX2016006656A (es)	2016-09-06
CN105744949A (zh)	2016-07-06
KR20160079821A (ko)	2016-07-06
US20180104319A1 (en)	2018-04-19
CY1121298T1 (el)	2020-05-29
ES2708655T3 (es)	2019-04-10
US20150147319A1 (en)	2015-05-28
KR102384814B1 (ko)	2022-04-08
JP2021063141A (ja)	2021-04-22
SMT201900042T1 (it)	2019-02-28
EP3071219A1 (de)	2016-09-28
PT3071219T (pt)	2019-02-06
PL3071219T3 (pl)	2019-04-30
JP2019023233A (ja)	2019-02-14
US20200360495A1 (en)	2020-11-19
LT3071219T (lt)	2019-01-10
JP2022179637A (ja)	2022-12-02
US9895428B2 (en)	2018-02-20
NZ759187A (en)	2022-08-26
CA2930964A1 (en)	2015-05-28
RS58343B1 (sr)	2019-03-29
CN111388655A (zh)	2020-07-10
BR112016011499A2 (pt)	2020-10-27

Publication	Publication Date	Title
MX2021000332A (es)	2021-04-13	Metodos para tratar rechazo mediado por anticuerpos en pacientes de trasplante de organos con inhibidor de c1-esterasa.
SG11202002169TA (en)	2020-04-29	Composition and method for treating autism
MX382562B (es)	2025-03-13	Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub).
IL285631A (en)	2021-09-30	Methods for producing autologous t cells useful to treat cancers and compositions thereof
NZ709635A (en)	2019-10-25	Bcl-2bcl-xl inhibitors and therapeutic methods using the same
MX2021013665A (es)	2021-12-10	Proteinas de union a calicreina en plasma y usos de las mismas para tratar el angioedema hereditario.
CL2014001162A1 (es)	2014-12-05	Inoculantes microbianos que comprenden lactobacillus; composicion fertilizante que comprenden los mismos; metodo para aumentar crecimiento y/o la productividad de plantas.
GB2538178A (en)	2016-11-09	Viscosifier polymer for treatment of a subterranean formation
AR093310A1 (es)	2015-05-27	Composiciones y metodos para mejorar el crecimiento de las plantas
PH12015500694A1 (en)	2015-05-25	Compositions and methods for enhancing plant growth
MX2015013622A (es)	2016-02-25	Composiciones y metodos para potenciar el crecimiento de las plantas.
NZ703411A (en)	2017-09-29	Use of markers in the diagnosis and treatment of prostate cancer
EP3458099A4 (de)	2020-07-22	Zusammensetzungen und verfahren zur behandlung von acne vulgaris
EP3138399A4 (de)	2017-12-06	Zusammensetzung für organ-, gewebe- oder zelltransplantation, kit und transplantationsverfahren
MX377593B (es)	2025-03-10	Composiciones para usar en el tratamiento de cáncer renal.
MX342676B (es)	2016-10-07	Anticuerpos anti-cd52 humanizados.
MX366208B (es)	2019-07-02	Transformación de la lenteja de agua y sus usos.
EP3609312C0 (de)	2023-08-16	Pflanzenwachstumsmedien und verfahren zur herstellung davon
MX2015012681A (es)	2018-05-17	Composiciones y metodos para tratar patogenos fungicos y bacterianos.
TW201611841A (en)	2016-04-01	Method for treatment of prostatic hyperplasia and/or ameliorating urinary disturbance with banana flower extract
MX2014013049A (es)	2015-03-19	Composiciones y metodos para sulfato de heparan como un biomarcador para rechazo de trasplante.
EP2408804A4 (de)	2012-10-03	Impfstoffzusammensetzungen und verfahren zur behandlung von mukormykose und anderen pilzerkrankungen
EP3064576A4 (de)	2016-11-02	Polypeptidzusammensetzung und kultivierungsverfahren für pluripotente stammzellen damit
IN2015DN03329A (de)	2015-10-23
MX2017007297A (es)	2018-03-12	Composiciones y metodos para la introduccion de micronutrientes.